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Abstract
Diabetes mellitus is a chronic multi-organ metabolic disorder caused by a combination
of  environmental  and genetic  factors.  Diabetic  complications  are  considered to  be
multifactorial with increasing evidence that one of the major pathways involved in the
progression  of  both  microvascular  and  macrovascular  diseases  is  the  biochemical
process of advanced glycation.
We will combine in vitro and in vivo studies and other related literatures to discuss the
role of advanced glycation end products (AGEs), which may exert deleterious effects in
diabetes. Dr Shuliang Lu puts forward the theory of ‘cutaneous environmental disor-
ders’ mediated by AGEs. The receptor for advanced glycation end products (RAGE) was
first described as a signal transduction receptor for AGEs. Recent discoveries regarding
AGEs-RAGE interactions expanded our understanding of the mechanisms by which
RAGE evoked pathological consequences.
In this chapter, we report on the biology of AGEs, AGEs and wound healing, as well as
address current strategies to interrupt the formation of AGEs and underscore strategies
by which antagonism of RAGE and AGEs-RAGE crosslinks may be realized.
Keywords: diabetic wound healing, advanced glycated end products, RAGE, meas-
urement, treatment
1. Introduction
Diabetes mellitus is characterized by chronic hyperglycemia and an altered cellular homeo-
stasis, which lead to diffuse vascular damage and multi-organ dysfunction. Diabetic patients
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risk both micro- and macro-vascular complications: the former result from damage to reti-
nal, renal, and neural tissues, which is the cause of blindness, end-stage renal failure, and
non-traumatic lower limb amputation, respectively [1]. Here, we will focus on diabetic
wound. Impaired wound healing is associated with increased morbidity and mortality in
diabetes mellitus. The majority of non-healing wounds often lead to amputation, increasing
the direct costs of their care, rehabilitation, and lost productivity [2].
According to a national survey, the prevalence of chronic cutaneous wounds among hospital-
ized patients was 1.7% in China. The leading causes were diabetes (31.3% men, 35.3% women)
and trauma (26.4% men, 19.2% women). Therefore, diabetes has recently become the leading
cause of chronic cutaneous wounds in China [3]. In Shuliang Lu’s study, it was indicated that
new diabetic foot ulcers were already in poor condition when patients first visited the diabetic
foot clinic. Concomitantly, patients had worse health-related quality of life compared with the
general population [4].
Several mechanisms have played a role in this condition, such as neuropathy, peripheral
arterial disease, biomechanical factors, infection, and wound healing. Brownlee identifies the
production of reactive oxygen species (ROS) as the unifying mechanism behind the main
pathological pathways triggered by hyperglycemia, one of which leads to the formation of
heterogeneous moieties called advanced glycation end products (AGEs) via non-enzymatic
glycation and glycoxidation processes [5]. AGEs affect the wound healing process either
directly by their interference with various components involved or indirectly through their
association with diabetic neuropathy or angiopathy [6, 7]. In addition, RAGE was discovered
as a receptor for AGEs, such as carboxymethyl lysine (CML) [8]. RAGE has been postulated
to contribute to the development of diabetic complications [9]. The mechanism of RAGE has
also been widely discussed.
In this chapter, we will present data regarding the formation and the metabolism of AGEs, the
role of RAGE involved in diabetic conditions, evidence emerging from in vitro and in vivo
studies as well as studies using anti-AGEs and other related agents to support a pathogenic
role for AGEs in the impaired process of diabetic wound healing.
2. AGEs formation
It was not until 1980 that the pathophysiological significance of AGEs emerged in medical
science, particularly in relation to diabetic complications [10]. AGEs are a heterogeneous group
of molecules that form from the non-enzymatic addition of sugar moieties onto arginine and
lysine residues of proteins, free amino groups on lipids, or guanine nucleic acids [11]. Glycation
has to be distinguished from glycosylation, which is an enzymatic reaction. First described by
Louis Camille Maillard in the 1900s, non-enzymatic glycation involves condensation reaction
of the carbonyl group of sugar aldehydes with the N-terminus or free-amino groups of proteins
via a nucleophilic addition, resulting first in the rapid formation of a Schiff base. The physio-
logical consequences of the Maillard reaction in the etiology of a range of important diabetic
complications have already been indicated [12]. The Schiff base then goes through rearrange-
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ments to form the more stable Amadori products. Among most cellular and plasma proteins,
Amadori products can change with glucose. That is to say, the levels of Amadori products will
rise and fall depending on the levels of glucose. The most well-known example of an Amadori
product is hemoglobin A1c (HbA1c), a naturally occurring modification to the N-terminal
valine amino group of the β chain of hemoglobin [13]. Schiff bases and Amadori products are
reversible reaction products. However, they can react irreversibly with amino acid residues of
peptides or proteins to form protein adducts or protein crosslinks [14] (Figure 1).
Figure 1. Schematic presentation of the Maillard reaction. Reactive carbonyl groups of a reducing sugar react with neu-
trophilic free amino groups of proteins to form a reversible Schiff base. Through rearrangement, a more stable Ama-
dori product is formed. Depending on the nature of these early glycation end products, protein adducts or protein
crosslinks are formed. (Illustrated from Ref. [54]).
In the context of intracellular glycation, it is important to note that glucose has the slowest rate
in the glycation reaction of any sugar [15]. Because of the slow formation, it is believed that
AGEs accumulate only on long-lived extracellular proteins. However, later a rapid extracel-
lular AGEs formation on short-lived proteins and intracellular AGEs formation by reactive
dicarbonyl compounds have attracted attention [16]. Thus, glycolytic intermediates such as
dihydroxyacetone-phosphate, glyceraldehyde-3-phosphate and the dicarbonyl compounds
glyoxal, methylglyoxal, and 3-deoxyglucosone are important for the intracellular Maillard
reaction [17]. Among these compounds, methylglyoxal is regarded as the most potent
glycating agent [18]. The transformation of glyceraldehyde-3-phosphate and dihydroxyace-
tone-phosphate formed methylglyoxal [19]. It could be detoxified by the conversion to S-
Dlactoylglutathione and D-lactate, catalyzed in the cytosol of all cells by glyoxalase I and II. It
has been reported that overexpression of glyoxalase I in endothelial cells completely prevented
AGEs formation, thus indicating the importance of methylglyoxal to form AGEs [20]. More-
over, several studies on different animal models have established that dietary AGEs could play
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an important role in the pathogenesis of various pathologic conditions and their complications,
such as type 1 diabetes mellitus in non-obese diabetic mice [21], atherosclerosis in apoE-
deficient mice [22], type 2 diabetes, and impaired wound healing in db/db (+/+) mice [23]. It
should be emphasized that a large portion of AGEs in the human body is derived from
exogenous sources, e.g. from regular food, smoking, etc. [24]. Much attention has been paid to
the so-called exogenous AGEs, harmful products of “browning” (or the Maillard reaction) in
various foods. Together with endogenous AGEs, these compounds form the majority of
glycation-free adducts. Among the various food processing methods, heating, sterilizing, and
microwaves contribute to the generation of exogenous AGEs, all of which tend to accelerate
the non-enzymatic addition of non-reducing sugars to free NH2 groups of proteins and lipids
[25].
3. RAGE
AGEs could exert their actions not only directly but also through a receptor system, which
includes two types of cell surface AGEs receptors: first type is that binds AGEs and initiates
cell activation and second type is that binds and degrades AGEs. Receptor for AGEs (RAGE)
is one receptor of the first type; it recognizes AGEs and initiates oxidative stress. The second
type of receptors consists of AGER1, AGER3, and CD36 [26, 27]. However, it is noteworthy
that there are other AGE receptors, such as the macrophage scavenger receptor and the
galectin-3 receptor, which might have similar deleterious effects to RAGE when they interact
with AGEs [28].
RAGE is a multi-ligand receptor of the immunoglobulin superfamily of cell surface molecules
acting as a receptor not only for several molecules including AGEs but also for S100/calgra-
nulins and amyloid. Circulating isoforms of RAGE include soluble RAGE (sRAGE) that has
been cleaved from the cell surface by matrix metalloproteinases and endogenous secretory
RAGE (esRAGE), and a splice variant of RAGE that is secreted into blood. Both sRAGE and
esRAGE protect body against the AGEs-elicited tissue damage by acting as a decoy receptor
for AGEs [29, 30]. The ligands of RAGE have a common feature that they accumulate in tissues
during aging, inflammation, and degenerative diseases. Engagement of RAGE results in
intracellular signaling that leads to the activation of NF-kB, a pro-inflammatory transcription
factor, which is then translocated to the nucleus and subsequently activates the transcription
of target genes [31]. These include genes of cytokines, adhesion molecules, and prothrombotic
and vasoconstrictive products. The activation of NF-kB results in upregulation of the receptors
in return. In addition, cellular-signaling cascades such as the ERK signaling pathway and PI-3
kinases are activated by the binding of ligands with RAGE [32].
In the skin, RAGE expression was observed in both epidermis and dermis, and it was increased
in sun-exposed compared with UV irradiation-protected areas [33]. Not only in vivo, but also
in vitro, various skin cells types have been shown to express RAGE [34–36], such as keratino-
cytes, fibroblasts, dendritic cells, and to a lesser extent endothelial cells and lymphocytes.
Patients with diabetes also exhibit increased immunoreactivity for RAGE and AGEs. For
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example, in sural nerve biopsies, AGE-RAGE interaction was found which suggests it may
have a clinical role in neuronal dysfunction that leads to neuropathy [37].
According to these reactions, researchers have put forward mechanisms by which AGEs lead
to diabetic complications: (1) the accumulation of AGEs in the extracellular matrix causing
aberrant crosslinking, resulting in a decrease of elasticity of vessels; (2) intracellular AGEs
formation leading to quenching of nitric oxide and impaired function of growth factors [20];
(3) the binding of AGEs to AGE-receptors on different cell types and activation of key cell
signaling pathways such as NF-kB activation with subsequent modulation of gene expression
in vascular cells such as endothelial cells, smooth muscle cells, and macrophages [38].
4. AGEs and wound healing
It is generally believed that wound healing is impaired in diabetes. Wound healing is a complex
process in which several pathophysiological processes are involved. They include inflamma-
tion, repair, and regeneration. Until now, there is evidence from experimental studies that
glycation is involved in wound healing in diabetes.
4.1. AGEs and inflammation phase in a diabetic wound
In this part, the interaction between AGEs and RAGE could not be neglected. Data support
that it negatively affects various aspects of inflammatory response in diabetic wound. In-
creased RAGE expression has been found in wound tissues from diabetic mice in parallel with
increased AGEs accumulation and increased inflammation [39]. In Shuliang Lu’s study [40],
compared with the controls, enhanced expression of RAGE and accelerated cell apoptosis were
observed in the burned skin of diabetic rats. The altered expression pattern of inflammatory
cytokines and oxidative markers between diabetic and control groups revealed delayed
neutrophil chemotaxis and respiratory burst. Furthermore, the results in vitro showed that
exposure to AGEs inhibited the viability of neutrophils, promoted RAGE production and cell
apoptosis, which was consistent with the findings in vivo. Besides, the mice fed with a rich
AGEs diet demonstrated an increased and sustained inflammatory phase compared with those
fed with a low AGEs diet [41]. In vitro, human neutrophils were isolated and treated with
AGE-human serum albumin. Cell viability and reactive oxygen species levels were increased
[42].
In keratinocytes, AGEs decrease cell viability and migration and induce the expression of
proinflammatory mediators as well [43]. Various growth factors or proteins significant for
cellular functions may be glycated inhibiting their functions [44]. Furthermore, treatment of
murine macrophages with AGEs resulted in increased levels of iNOS, which has been found
to be increased in diabetic wounds [45]. Macrophages play a critical role in wound healing and
can be activated to two distinctive phenotypes in vitro: M1 and M2 [46]. It demonstrated
insufficient M1 in the early stage but excessive M2 in the later proliferative phase. The
macrophage activation markers were correlated with the instructive T helper cell type 1 (Th1)/
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Th2 cytokines in both groups. Other studies suggested that RAGE expression has been strongly
linked to the expression of matrix metalloproteinases (MMP)-1, MMP-3, MMP-9, mainly
through RAGE engagement by AGEs [47]. In addition, AGEs induced the production of
oxygen-reactive intermediates from inflammatory and endothelial cells via NADPH activation
probably through their receptors, promoting further cellular activation and proinflammatory
cytokine expression [48].
4.2. AGEs and proliferation phase in the diabetic wound
It has been reported that the presence of AGEs not only affected the interaction of the fibroblasts
with the extracellular matrix but also reduced the amount of the extracellular matrix as well.
This effect would influence almost all the cells involved in the proliferative process. In vitro
incubation of human dermal fibroblasts with pentosidine or pyrraline resulted in reduction of
the extracellular matrix content, which was collagen and proteoglycan [49]. In vitro study
showed that type I collagen synthesis from fibroblasts was not affected in AGEs; however, the
synthesis of hyaluronic acid was significantly reduced [50]. It also showed a direct effect of
AGEs on fibroblast synthetic capacity and explained the decreased extracellular matrix in the
diabetic wound. Because hyaluronic acid is associated with cellular locomotion, migration,
and proliferation, decreased content in the matrix could result in disturbance of the prolifer-
ative phase of the healing process. Besides, histological evaluation of wound sections from
diabetic rats demonstrated absence of actively migrating inflammatory cells toward the central
region of the wound, reduced angiogenesis, a decrease in the secretion of extracellular matrix,
and then poor granulation tissue formation [51].
AGEs may also change the action of the wound-associated cytokines and growth factors, by
affecting the growth factors or their receptors. Glycation of bFGF, after its incubation with
glucose-6-phosphate (G6P) or fructose, resulted in decreased heparin-binding capacity, which
is necessary for the binding of bFGF to its receptor. A reduction in its mitogenic activity was
also observed compared with the control bFGF group [45]. In addition, incubation of FGF2
with G6P resulted in glycation of FGF2. Bovine aortic endothelial cells incubated with the
glycated FGF2 showed a reduction of proliferation, decreased mean capillary length and new
blood vessel formation, a weaker increase in tyrosine-phosphorylated proteins, especially
ERK-1 and ERK-2 [52] .While ECV304 cells were incubated with glyoxal proteins, a significant
reduction in the free amino acid groups of the EGF receptors was found. It also showed that
the EGF-induced recruitment and activation of the downstream effectors of the EGF receptor
pathway PLCg1 and ERK1/2 was inhibited by AGEs [53]. Furthermore, an animal study using
rats with subcutaneous implantation of sponge disks showed that pretreatment of animals
with D-glucose resulted in a reduction in the angiogenesis measured by the hemoglobin
content of the implanted disks and a reduction in the granulomatous response compared with
control groups.
4.3. AGEs and remodeling phase in the diabetic wound
Every stage of normal wound healing appears to be disrupted in the diabetic patients. A
derangement in wound contraction and remodeling is expectable. A large body of evidence
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supports the effects of AGEs on the phenotype, invasiveness, behavior, and survival of the cells
and cell membrane interactions with extracellular matrix. Animal data showed that diabetic
mice with lower circulating and tissue-bound AGEs as a result of exposure to a diet low in
AGEs, showed improved reepithelialization, granulation tissue formation and angiogenesis
compared with the group fed with a diet high in AGEs [54].
Figure 2. Immunohistochemical localization of AGE and RAGE proteins in dermis is shown. A, B, The distribution of
AGE in normal skin tissue (A) and in diabetic skin tissue (B). AGE protein staining was expressed faintly at dermal
matrices and cells in control skin but was prominent at the dermal matrices, cells, and basement membrane of vessels
in the diabetic skin. C, D, The distribution of RAGE in normal skin tissue (C) and in diabetic skin tissue (D). RAGE-
positive cells appear brown, and a light hematoxylin counter stain was used to visualize nuclei. More positive cells
were detected in diabetic dermal layer than in control. [Original magnification, ×200 (A, B); original magnification, ×400
(C, D)]. (Illustrated from Ref. [55]).
The balance between proliferation and apoptosis of skin cells is responsible for the success of
the wound healing process. Recent reports have shown that AGEs formation participates in
dermatologic problems in diabetes. Shuliang Lu’s group reported that effects of dermal micro-
environment glycosylation. Histology and immunohistochemical staining were performed on
type 2 diabetic and nondiabetic skin specimens to determine the distributions of proliferating
cell nuclear antigen, apoptotic cells, AGEs and RAGE. Diabetic skin has degenerative, loosely
arranged collagen and increased apoptotic cells compared with normal skin. Expression of
AGEs and RAGE were increased in diabetic skin. Glycosylated matrix induced cell cycle arrest
and apoptosis of cultured dermal fibroblasts, whereas application of RAGE-blocking antibod-
ies redressed these changes [55] (Figure 2).
AGEs may alter the signaling of the wound cytokines and growth factors by disrupting the
structure of either the growth factors or their receptors. Glycation of fibroblast growth factor
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(bFGF), after its incubation with intracellular sugars resulted in decreased heparin-binding
capacity, which is essential for the ligation of bFGF to its receptor [56]. Bovine aortic endothelial
cells incubated with the glycated FGF-2 showed a reduction in the proliferation, decreased
mean capillary length and overall new blood vessel formation as well as a clearly weaker
increase in tyrosine phosphorylated proteins, particularly ERK-1 and ERK-2 [57]. It has also
been shown that the epidermal growth factor (EGF)-induced recruitment and activation of the
downstream effectors of the EGF receptor pathway, the serine-threonine kinases ERK1/2, was
inhibited by glyoxal and methylglyoxal [58]. Moreover, diabetic rats exhibited poor TGF-β1
expression in fibroblasts [20]. The effects of TGF-β1 on extracellular matrix synthesis and
cellular phenotypes are crucial for the final stage of wound healing, suppression of MMP
secretion, differentiation of fibroblasts into contractile myofibroblasts, and cellular program-
med death. The increased levels of MMPs and proinflammatory cytokines in the context of a
vicious self-perpetuating cycle of an inappropriately inflammatory response may be respon-
sible for the derangement of the remodeling stage [42].
Literature data also support that in the presence of AGEs, not only the interaction of the
fibroblasts with the extracellular matrix is affected, but also the amount of the extracellular
matrix constituents normally secreted by cells is reduced. This effect would deprive almost all
the cells involved in the proliferative process of the extracellular scaffold [59]. In vitro, studies
showed a direct effect of AGEs on fibroblast survival and synthetic capacity, which might
partially explain the decreased extracellular matrix density in the diabetic non-healing
wounds. Human adult primary skin fibroblasts treated with CML-collagen (glycated collagen)
showed a time- and dose-dependent apoptosis, which was threefold compared with that of
control collagen-treated fibroblasts [60]. An insight has been gained into the mechanisms that
underlie the AGEs-promoted cell apoptosis. The proapoptotic intracellular signaling consists
of involving a chain of events, such as the generation of intracellular reactive oxygen species,
which cause the activation of mitogen-activated protein kinase (MAPK) pathways and finally
the induction of transcription factor FOXO1 and caspase-3. In addition, keratinocytes pre-
treated with glycoaldehyde and type I collagen exhibited reduced migration and an impaired
adhesive capacity [61]. These effects were caused by conformational changes on the glycated
collagen, which altered the effective receptor binding [62]. Furthermore, increased AGE/RAGE
expression has been found in the diabetic skin. The apoptotic effects could be reversed by the
application of RAGE antibodies, suggesting that AGEs and RAGE interaction played an
important part in the cell dysfunction [40].
Another study of Shuliang Lu’s group demonstrated that thickness of abdominal dermis
from diabetic patients was reduced with obscured multilayer epithelium and disorganized
collagen fibrils, as well as with chronic inflammatory cell infiltration. It was also shown that
the prominent accumulation of AGEs in the diabetic skin induced an oxidative damage of
fibroblasts and thus contributed to the thinner thickness of diabetic abdominal dermis. In
vivo, less hydroxyproline, higher myeloperoxidase activity, and increased malondialdehyde
(MDA) content were found in the diabetic skin. In vitro, the time- and dose-dependent in-
hibitory effects of AGE-bovine serum albumin (BSA) on fibroblast viability and the promo-
tion of MDA production were shown [63].
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5. Measurement of AGEs
Since the biochemistry of AGEs has been widely discussed, the effort to develop the meas-
urement has been made as well. Blood is more accessible for repeated measurements of
AGEs than tissue-requiring biopsies, but plasma AGEs assays have not yet been shown to
be directly related to tissue AGEs content [64]. As tissue accumulation of AGEs proves a
long-term course with low reversibility, the AGEs accumulated in long-lived tissue proteins
like skin collagen may be a carrier of metabolic memory over a long period, even years [65].
Because certain AGEs have intrinsic fluorescence properties, tissue AGEs accumulation can
be assessed as skin autofluorescence (SAF) by the AGE Reader™ (Diagn-Optics, Groningen,
the Netherlands) easily and noninvasively [66], instead of other traditional invasive techni-
ques (Figure 3). Several studies demonstrated that the SAF value obtained from the skin of
the lower arm correlated with content of both fluorescent and nonfluorescent AGEs meas-
ured from skin biopsy specimens on the same site [67]. It is strongly related to AGEs accu-
mulation in healthy subjects, and diabetic and hemodialysis patients over a broad age range
[68]. There is no surprise that SAF values of the diabetic patients were significantly higher
than the healthy population [69, 70], and SAF values of diabetes with complications were
elevated compared with those without complications [71, 72]. So far, there have been SAF
referential values and its influential factors for healthy Dutch, Slovakian, and Chinese peo-
ple, and this offers the baseline values to further analyze diabetes and its chronic complica-
tions [73–75].
However, studies of SAF on predicting the diabetic vascular complications were of consider-
able clinical heterogeneity, and different experimental results were adjusted in different
conditions [76, 77]. Recent publications have suggested that SAF serves as a marker of vascular
damage [78], as well as a predictor of cardiac mortality in patients with type 1 and 2 diabetes.
In Shuliang Lu’s group, Liu Chuanbo et al. did a cross-sectional survey consisting of 118
consecutive hospitalized diabetic foot patients. The diabetic microvascular (retinopathy,
nephropathy, and neuropathy) and macrovascular referring to coronary heart disease (CHD),
cerebrovascular disease (CVD), or peripheral artery disease (PAD) complications were
evaluated .The mean SAF value was 2.8 ± 0.2 AU. SAF was significantly associated with
diabetes duration and blood urea nitrogen (R2 = 62.8%; P < 0.01). Moreover, in logistic
regression analysis, SAF was significantly associated with retinopathy (odds ratio [OR] =
40.11), nephropathy (OR = 8.44), CHD (OR = 44.31), CVD (OR = 80.73), and PAD (OR = 5.98 ×
109). Therefore, SAF, reflecting tissue accumulation of AGEs is independently associated with
the presence of micro-and macro-vascular complications in diabetic foot ulcer (DFU) patients
[79]. Similarly, SAF values were significantly higher in type 1 diabetic patients with microvas-
cular complications, like neuropathy, compared to those without complications [80]. Lisanne
et al. reported that SAF was independently associated with all-cause mortality and fatal or
non-fatal major adverse cardiovascular events in patients with peripheral artery disease after
a 5-year follow-up [81].
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Figure 3. (A) The autofluorescence reader illuminates a skin surface with an excitation light source between 300–420
nm. Only light from the skin is measured with a spectrometer. (B) Various fluorescence spectrum results from different
subjects: healthy subject (black line), diabetic patient without cardiovascular complications (blue line), diabetic patient
with peripheral artery occlusive disease (green line), hemodialysis patient with recent myocardial infarction (red line).
I = intensity (a.u.). (Illustrated from Meerwaldt R, van der Vaart MG, van Dam GM, et al. Clinical relevance of ad-
vanced glycation end products for vascular surgery. Eur J Vasc Endovasc Surg. 2008;36(2):125–31).
The use of SAF in the diabetic wound was also discussed. Meerwaldt et al. showed that SAF
was increased and correlated with the Wagner score in DFU with neuropathy. SAF correlated
inversely with nerve conduction velocity and amplitude [82]. Lapolla et al. found that AGEs
were higher in type 2 diabetics with PAD compared to those without PAD; AGEs were
correlated inversely to ABPI, even after correction for other cardiovascular risk factors [83].
SAF is independently associated with diabetic foot ulcerations. It might be a useful screening
method for foot ulceration risk of diabetic patients [77].
Use of SAF measurement to assess foot vulnerability and to predict DFU events in high-risk
patients seems to be promising. Yet, Vouillarmet et al.’s study in a subgroup of patients with
an active DFU showed a nonsignificant correlation (P = 0.06) between SAF and the incidence
of healing at 2 months, but the magnitude of effect is still high. Therefore, researchers deemed
that the small number of patients may be the reason for the lack of statistical power. SAF
method deserves attention because of its prognostic value for healing [84].
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However, long-term studies validating both the specificity and sensitivity of this investigation,
and its link to certain AGEs, remain to be confirmed. The importance of its use in the follow-
up of DFU is not reported. Thus, AGEs might have some value as a screening tool for DFU,
but there is no strong evidence for other clinical use in diabetic wound, and AGEs measure-
ments should not be considered a replacement for HbA1c as a marker of glycemic control.
6. Anti-AGEs strategies
Since AGEs were considered as an important factor in diabetes, the development of strategies
against AGEs has been of interest. Substances, which can prevent or inhibit the formation of
AGEs, as well as agents that can break AGEs or antagonize their signaling have been identified.
6.1. Inhibit the formation of AGEs
The first approach is to reduce the formation of AGEs by intervention at one of the steps
involved such as aminoguanidine [85]. Aminoguanidine was one of the first substances
identified limiting the formation of AGEs [86]. It is a highly reactive nucleophilic reagent that
prevents the formation of AGEs by reacting with the carbonyl groups as well as alpha- and
beta-dicarbonyl compounds such as methylglyoxal, glyoxal, and 3-deoxyglucosone. Particu-
larly, long-term aminoguanidine treatment improved the nerve conduction deficit and
myelinated fiber pathology in diabetic rats in vivo [87]. A double-blinded, multiple-dose,
placebo-controlled, randomized clinical trial of aminoguanidine in diabetic patients with overt
diabetic nephropathy (ACTION) was completed in 1998; ACTION I involved 690 type 1
diabetic patients and ACTION II involved 599 type 2 diabetic patients. These studies were
designed to evaluate the safety and efficacy of aminoguanidine in slowing the rate of renal
disease progression in patients with overt diabetic nephropathy. However, ACTION II was
terminated prematurely due to safety concerns and apparent lack of efficacy. Reported side
effects included gastrointestinal disturbance, liver function abnormalities, flu-like symptoms,
and a rare vasculitis [88]. Its use in clinical practice is limited due to adverse effects in clinical
trials with diabetic patients. Despite the earlier promising results, aminoguanidine is unlikely
to be used for therapeutic purpose due to safety concerns and lack of efficacy [89]. Studies on
topical application of aminoguanidine on the skin are still lacking.
Metformin that is routinely used in the treatment of type 2 diabetic patients has some structural
similarities to aminoguanidine and it was shown that in type 2 diabetes, treatment with
metformin reduced levels of methylglyoxal [90]. Pyridoxamine is a natural intermediate of
vitamin B6 metabolism and a potent inhibitor of the formation of AGEs [91]. Pyridoxamine
traps reactive carbonyl intermediates and scavenges ROS. In addition, it inhibits post-Amadori
stages of AGEs formation. Marked effects of pyridoxamine such as delayed development of
nephropathy and retinopathy have been demonstrated in diabetic rats. Its oral intake could
result in potent inhibition of skin collagen CML formation in diabetic rats as well [92].




RAGE is the most studied receptor for advanced glycation end products. AGER1 has been
shown to counteract AGEs-induced oxidative stress via inhibition of RAGE signaling [93].
sRAGE is a truncated splice variant of RAGE containing the ligand-binding domain but not
the transmembrane domain and has been found in plasma. sRAGE is a soluble extracellular
protein without signaling properties and it is considered as a natural decoy receptor of RAGE
[30].
Blockage of RAGE by sRAGE may be a new target for therapeutic intervention in diabetic
disorders. Potential protective effects of sRAGE have been shown in various diabetes and
inflammatory models [94]. Interestingly, sRAGE could also attenuate impaired wound healing
in diabetic mice. Other promising effects in various systems have been shown in vitro and in
vivo with neutralizing anti-RAGE antibodies [31]. Possible approaches include gene knock-
down of RAGE by siRNA or anti-sense and antagonism of RAGE with putative small molecular
inhibitors against RAGE-induced signaling [95].
6.3. AGEs breakers
Chemical substances and enzymes that are able to recognize and break the Maillard reaction
crosslinks have been identified. Such chemical AGEs breakers are dimethyl-3-phenayl-
thiazolium chloride (ALT-711) [64], N-phenacylthiazolium and N-phenacyl-4,5-dimethylthia-
zolium. Promising results against diabetic cardiovascular complications have been reported,
though their actual ability to cleave existing protein crosslinks in tissues has been questioned
[96]. However, treatment with ALT-711 for 2 weeks had no effects on motor nerve conduction
deficit, C-fiber-mediated nociceptive dysfunction, or impaired pressure-induced vasodilation
in diabetic mice [97].
Interference with intrinsic AGE-detoxifying enzymes like fructosyl-amine oxidases (FAOXs),
fructosamine-3-kinase (FN3K), and the enzymatic system of glyoxalase I is another interesting
strategy to remove AGEs, because enzymes could recognize specific substrates [60]. It is
reported that overexpression of glyoxalase I significantly inhibits hyperglycemia-induced
intracellular formation of AGEs in bovine aortic endothelial cells and in mouse mesangial cells
by reduction of intracellular oxidative stress and apoptosis [98]. The pharmacological induc-
tion of such enzymes could represent a novel future strategy against AGEs.
Other anti-AGE agents, including the thiazolidine derivative named OPB-9195, have been
investigated [99]. OPB-9195 has been shown to prevent the progression of diabetic nephrop-
athy in rats. It has also been demonstrated to improve motor nerve conduction slowing without
affecting body weight and blood glucose levels. The improvement was associated with reduced
serum AGEs levels and peripheral nerve expression of AGEs and immunoreactive 8-hy-
droxy-2-deoxyguanosine, which is a marker for oxidative stress-related DNA damage as well
as an increase in peripheral nerve (Na+, K+)-ATPase activity [100].
Diabetic rats were found to have increased mesenteric vascular AGEs accumulation and
mesenteric vascular hypertrophy, both of which were prevented by treatment with N-
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phenacylthiazolium bromide (PTB) [101]. A more recent study has demonstrated that although
AGE-breakers such as PTB and N-phenacyl-4,5-dimethylthiazolium cleave model crosslinks
in vitro, they do not significantly cleave AGE crosslinks formed in vivo in skin collagen of
diabetic rats [59].
Benfotiamine, a lipophilic analogue of thiamine, is a transketolase activator that inhibits three
of the four major biochemical pathways implicated in the pathogenesis of hyperglycemia-
induced vascular damage: the hexosamine pathway, PKC activation, and AGEs formation
[102]. In diabetic rats, nearly normalized nerve conduction velocity and inhibition of neural
imidazole-type AGEs and CML formation after 6 months of benfotiamine treatment were
observed [103]. In both nondiabetic and diabetic rats, benfotiamine also reduced inflammatory
and neuropathic nociception [104].
6.4. Nutrient substance
An increasing list of natural antioxidants and chelating agents such as ascorbic acid, α-
tocopherol, niacinamide, pyridoxal, sodium selenite, selenium yeast, trolox, rivoflavin, zinc,
and manganese has been shown to inhibit glycation of albumin in vitro [105]. Many spices and
herbs could inhibit glycation of albumin in vitro as well, such as ginger, cinnamon, cloves,
rosemary, and tarragon [106]. Besides, green tea, vitamins C and E, and a combination of N-
acetylcystein with taurine and oxerutin could inhibit skin collagen glycation in mice [107]. In
healthy human subjects, supplementation of vitamin C significantly decreased serum protein
glycation [108].
Alpha-lipoic acid could reverse tail tendon collagen glycation in fructose-fed rats, an effect
which was attributed to its endogenous antioxidant action, its ability to recycle ascorbic acid
and GSH, as well as to its positive influence on glucose uptake and glycemia [109]. Blueberry
extract, an AGE-inhibitor and C-xyloside, was tested for 12 weeks in female diabetic subjects.
This treatment resulted in significant improvement of skin firmness, wrinkles, and hydration.
However, it failed to show a significant decrease in the cutaneous content of AGEs [110].
6.5. Molecular chaperones
Molecular chaperones like carnosine have shown promise in improving skin appearance in
part by reducing the amounts of skin AGEs [111]. Yet, more studies are needed to address the
accumulation of AGEs in diabetic wound.
In conclusion, AGEs are a heterogeneous group of molecules that form from the non-enzymatic
addition of sugar moieties onto arginine and lysine residues of proteins, free amino groups on
lipids, or guanine nucleic acids. The AGE-RAGE interactions play an important role in the
diabetic wound healing process. The measurement of AGEs on the skin, namely, skin
autofluorescence might have some value as a screening tool for diabetic foot ulcer, but until
now, there is no strong evidence for other clinical use in diabetic wound. In addition, substances
which can prevent or inhibit the formation of AGEs, as well as agents that can break AGEs or
antagonize AGE/RAGE signaling have been identified.
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